BR112012011678A2 - composição e métodos para afetar a produção de citocinas e nf-kb - Google Patents

composição e métodos para afetar a produção de citocinas e nf-kb

Info

Publication number
BR112012011678A2
BR112012011678A2 BR112012011678A BR112012011678A BR112012011678A2 BR 112012011678 A2 BR112012011678 A2 BR 112012011678A2 BR 112012011678 A BR112012011678 A BR 112012011678A BR 112012011678 A BR112012011678 A BR 112012011678A BR 112012011678 A2 BR112012011678 A2 BR 112012011678A2
Authority
BR
Brazil
Prior art keywords
composition
production
various
methods
affecting
Prior art date
Application number
BR112012011678A
Other languages
English (en)
Portuguese (pt)
Inventor
Dahl Andrew
Callewaert Dennis
Martinez Enrique
Sarkar Fazlul
Thomas Tiffany
Original Assignee
Health Enhancement Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Enhancement Products Inc filed Critical Health Enhancement Products Inc
Publication of BR112012011678A2 publication Critical patent/BR112012011678A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112012011678A 2009-11-16 2010-11-16 composição e métodos para afetar a produção de citocinas e nf-kb BR112012011678A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26163909P 2009-11-16 2009-11-16
PCT/US2010/056862 WO2011060427A2 (en) 2009-11-16 2010-11-16 Composition and methods for affecting cytokines and nf-kb

Publications (1)

Publication Number Publication Date
BR112012011678A2 true BR112012011678A2 (pt) 2018-04-17

Family

ID=43992472

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011678A BR112012011678A2 (pt) 2009-11-16 2010-11-16 composição e métodos para afetar a produção de citocinas e nf-kb

Country Status (6)

Country Link
US (1) US20110117122A1 (https=)
EP (1) EP2501390A4 (https=)
JP (1) JP2013510905A (https=)
BR (1) BR112012011678A2 (https=)
CA (1) CA2780144A1 (https=)
WO (1) WO2011060427A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
JP2013520444A (ja) 2010-02-22 2013-06-06 ヘルス エンハンスメント プロダクツ インコーポレイテッド 高コレステロール血症を処置するための薬剤及び機序
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
WO2016133922A1 (en) 2015-02-16 2016-08-25 Zivo Bioscience, Inc. Methods of modulating immune and inflammatory responses via administration of an algal biomass
US11806375B2 (en) 2016-02-16 2023-11-07 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10480A (en) * 1854-01-31 Improvement in electro-magnettc engines
US15587A (en) * 1856-08-19 Aepabattts for boeing artesian wells
US9479A (en) * 1852-12-21 Improvement in rakes to grain-harvesters
JPS6219528A (ja) * 1985-07-16 1987-01-28 Kurorera Kogyo Kk 制癌剤
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
DE60012026T2 (de) * 1999-08-26 2004-12-30 Ganeden Biotech, Inc., San Diego Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
WO2001022834A2 (en) * 1999-09-27 2001-04-05 Algal Ltd. Vegetarian foodstuff
ATE265218T1 (de) * 2000-08-10 2004-05-15 Ocean Nutrition Canada Ltd Chlorella zubereitungen mit immunmodulatorischen eigenschaften
EP1409000A1 (en) * 2000-08-18 2004-04-21 Atlas World USA, Inc. Use of agaricus blazei murill to prevent or treat skin and other disorders
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
WO2004044161A2 (en) * 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US20130251698A1 (en) * 2010-10-04 2013-09-26 Health Enhancement Products, Inc. Composition and method for affecting cytokines and nf-kb
US7807622B2 (en) * 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US20080031863A1 (en) * 2004-04-23 2008-02-07 Health Enhancement Products, Inc. Method of Preparation and Use of Fibrinolytic Enzymes in the Treatment of Disease
US8586053B2 (en) * 2005-09-21 2013-11-19 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
CA2631773C (en) * 2005-12-02 2022-04-26 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease

Also Published As

Publication number Publication date
EP2501390A4 (en) 2014-07-02
CA2780144A1 (en) 2011-05-19
WO2011060427A9 (en) 2011-09-15
US20110117122A1 (en) 2011-05-19
JP2013510905A (ja) 2013-03-28
WO2011060427A2 (en) 2011-05-19
EP2501390A2 (en) 2012-09-26

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
NI201200030A (es) Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
NZ749217A (en) Androgen receptor modulator and uses thereof
MX2012009718A (es) Material biodegradable que contiene silicio para terapia antiinflamatoria.
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
EP2750694B8 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
MX365650B (es) Composiciones de amantadina y metodos para su uso.
BR112012018170B8 (pt) agente antimicrobiano para redução, inibição ou tratamento do crescimento microbiano, infecções microbianas, doenças inflamatórias, doenças ou condições virais resultantes de ou associadas aos mesmos
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
MX2014000150A (es) Sistemas, metodos y formulaciones para tratamiento de cancer.
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
BR112012011678A2 (pt) composição e métodos para afetar a produção de citocinas e nf-kb
UY32444A (es) Composiciones y procedimientos para terapia extendida con aminopiridinas
CO7240352A2 (es) Profármacos novedosos de rebampida, método de preparación y uso del mismo
MX341300B (es) Composiciones para el tratamiento de ulceras perifericas de varios origenes.
BR112012020934A8 (pt) Processo para purificação da alfa-manosidase lisossomal humana recombinante a partir de uma cultura celular, composição, processo em batelada alimentada ou produção contínua da alfa-manosidase lisossomal humana recombinante e uso da composição
GB2525517A (en) Topical preparation for pain relief
WO2011150175A3 (en) Compositions and methods for pain reduction
BR112017009237A2 (pt) composições de éster de forbol e métodos para tratar ou reduzir a duração de citopenia
IN2014DN03010A (https=)
MX2014010989A (es) Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos.
PH12014500739B1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
IN2014DN00123A (https=)
NZ711238A (en) Compositions and methods for treating multi-drug resistant malaria

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ZIVO BIOSCIENCE, INC. (US)

B25G Requested change of headquarter approved

Owner name: ZIVO BIOSCIENCE, INC. (US)

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal